key: cord-0739614-f15bafcr
authors: Agostinetto, Rita; Rossi, Mara; Dawson, Jessica; Lim, Angela; Simoneau, Mirva Hejjaoui; Boucher, Cyril; Valldorf, Bernhard; Ross‐Gillespie, Adin; Jardine, Joseph G.; Sok, Devin; Burton, Dennis R.; Hassell, Thomas; Broly, Hervé; Palinsky, Wolf; Dupraz, Philippe; Feinberg, Mark; Dey, Antu K.
title: Rapid cGMP Manufacturing of COVID‐19 monoclonal antibody using stable CHO cell pools
date: 2021-11-18
journal: Biotechnol Bioeng
DOI: 10.1002/bit.27995
sha: 5cbee347ee9c2a439d2b8d5e006d4657045698cc
doc_id: 739614
cord_uid: f15bafcr

Therapeutic proteins, including monoclonal antibodies, are typically manufactured using clonally‐derived, stable host cell lines, since consistent and predictable cell culture performance is highly desirable. However, selecting and preparing banks of stable clones takes considerable time, which inevitably extends overall development timelines for new therapeutics by delaying the start of subsequent activities, such as the scale‐up of manufacturing processes. In the context of the COVID‐19 pandemic, with its intense pressure for accelerated development strategies, we used a novel transposon‐based Leap‐In Transposase(®) system to rapidly generate high‐titer stable pools and then used them directly for large scale‐manufacturing of an anti‐SARS‐CoV2 monoclonal antibody under cGMP. We performed the safety testing of our non‐clonal cell bank, then used it to produce material at a 200L‐scale for pre‐clinical safety studies and formulation development work, and thereafter at 2000L scale for supply of material for a Phase 1 clinical trial. Testing demonstrated the comparability of critical product qualities between the two scales and, more importantly, that our final clinical trial product met all pre‐set product quality specifications. The above expediated approach provided clinical trial material within 4.5 months, in comparison to 12‐14 months for production of clinical trial material via the conventional approach. This article is protected by copyright. All rights reserved.

Article them directly for large scale-manufacturing of an anti-SARS-CoV2 monoclonal antibody under cGMP. We performed the safety testing of our non-clonal cell bank, then used it to produce material at a 200L-scale for pre-clinical safety studies and formulation development work, and thereafter at 2000L scale for supply of material for a Phase 1 clinical trial. Testing demonstrated the comparability of critical product qualities between the two scales and, more importantly, that our final clinical trial product met all pre-set product quality specifications. The above expediated approach provided clinical trial material within 4.5 months, in comparison to 12-14 months for production of clinical trial material via the conventional approach.

Multiple cell line sources are used as hosts to produce recombinant prophylactic and therapeutic proteins for human use. Recombinant CHO cell lines [1] remain a preferred host due to the reliability, robustness and maturity of the technology in generating clonally-derived cell line. Despite the high level of production, batch-to-batch consistency and robustness of a clonally-derived CHO cell line, the approach is challenging due to the burden of time and resources required for stable clone isolation, selection, and provision of tested cell banks for cGMP manufacturing. Therefore, in recent past, several groups have reviewed their cell line development strategy to expedite entry into clinic [2] [3] [4] [5] by generating comparison between non-clonal and clonal CHO cell produced materials [6] , and accelerating IND-enabling Toxicology studies by using materials produced from non-clonal CHO cell lines [7-10]. In addition to expediting the Toxicology study using materials from non-clonal CHO cell pools in non-cGMP production, as others have shown [7-10]. We wanted to evaluate the possibility of using non-clonal stable CHO cell pools to expediate production of a IgG1 monoclonal antibody (mAb) against SARS-CoV2, CC6.35, particularly through cGMP manufacturing of a single batch of material for a Phase 1 clinical trial. Since this approach (of producing material for early clinical studies using non-clonal CHO cell pools) has not been rigorously tested for scaled-up cGMP manufacturing and concerns remain that the cellular and genetic heterogeneity of non-clonal stable CHO cell pools may result in production variability and concomitant heterogeneous product qualities between batches, we present a case study wherein we used non-clonal qualified cell banks and platform processes to accelerate This article is protected by copyright. All rights reserved.

Article manufacturing of CC6.35 mAb. To do so, we used the novel transposon-based Leap-In Transposase ® system [11, 12] for the development of stable CHO cell lines. The codonoptimized DNA sequence encoding the amino acid sequence for the Heavy chain (HC) and Light chain (LC) of CC6.35 mAb along with corresponding signal peptide and the novel expression constructs based on the Leap-In transposon® system were designed and synthesized. These synthesized DNA constructs along with transposase mRNA [12, 13] were used to co-transfect HD-BIOP3 glutamine synthase (GS) knock-out CHO-K1 host cells. Two promoter components were used to generate two unique sets of CHO cell pools: one using the EF1 promoter and another using the CMV promoter. Posttransfection the recovery of these two CHO cell pools was performed; after the initial recovery phase, the positive CHO cell pools were selected by outgrowth in a glutaminefree formulation at 37°C in 5% CO 2 and 70-80% relative humidity and expanded further before cryopreservation and generation of Research Cell Banks (RCBs). In order to estimate productivity of the CC6.35 antibody-expressing stable CHO cell pools, both cell pools were expanded in a small-scale cell culture based on fed-batch process. After 14days, the harvested supernatant was measured for titer by binding to a Protein-A biosensor on the Octet ® System. Table 1 shows the percent (%) viability and expression levels (in g/L) for both EF1-CC6.35 and CMV-CC6.35 stable CHO cell pools.

Based on the higher titer, the CMV-CC6.35 cryopreserved RCB vials were advanced for use in scale-up production. This (CMV-CC6.35) RCB was tested for safety and regulatory acceptance for producing the two pivotal lots of material: one for preclinical safety studies and another for Phase 1 clinical trial. Prior entry of the RCBs in the cGMP facility, rapid safety test using PCR (Polymerase Chain Reaction) and NGS (Next-Generation Sequencing) based viral safety testing were performed to eliminate risk of adventitious contamination. In addition, the RCBs were also tested using compendial test for mycoplasma and sterility.

For producing material for pre-clinical safety study, the RCB vials were thawed and expanded using a seed-train to support a 200 L bioreactor. The key cell culture process indicators included cell growth, cell viability, metabolic profiles (for ammonia and lactate), bioreactor regulation profiles (for pH, glucose, osmolality and pCO 2 ) and antibody titer. This article is protected by copyright. All rights reserved.

In addition to results in Table 3 In summary, we demonstrate that using non-clonal stable CHO cell pools and use of platform processes can expediate early clinical development of monoclonal antibodies during pandemic outbreaks of emerging infectious such as COVID-19. We show that the antibodies produced from these stable CHO pools at two large scales bioreactors were comparable using platform upstream and downstream processes, and through robust analytical tested they were deemed suitable for clinical use. Since clinical development timeline continue to thwart rapid evaluation of therapeutic and prophylactic interventions during pandemics and therefore improvements in development span essential [14], we believe that this approach of using non-clonal stable CHO cell pools that enabled manufacturing of early clinical trial material within 4.5 months, is a feasible alternative for Accepted Article rapid cGMP manufacturing and a means that can accelerate the pace of therapeutic and prophylactic protein evaluation in clinic. 

Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects

Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak

Strategic deployment of CHO expression platforms to deliver Pfizer's Monoclonal Antibody Portfolio

Leveraging a CHO cell line toolkit to accelerate biotherapeutics into the clinic

Beyond preclinical research: production of CHO-derived biotherapeutics for toxicology and earlyphase trials by transient gene expression or stable pools. Current Opinion in Chemical Engineering

Comparative study of therapeutic antibody candidates derived from mini-pool and clonal cell lines

Comparison of parameters of the Drug Substances from 200L (non-cGMP) and 2000L (cGMP) production runs

We thank the various members of the Project Team at Merck KGaA and IAVI for their contributions. We thank Sowmya Rajendran, Lynn Webster, Surya Karunakaran and Ferenc Boldog at ATUM for Cell Line Development of the stable CHO cell line pools. We thank the members of the senior management team at Merck KGaA and IAVI for their support and guidance through the project.

The authors confirm that the data supporting the findings of this study are available within the article.